Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 10/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2479245 | 0.93 | POLB (0.43) | MKNK1ESR2POLBPARP1TNKS2 | |
| SCHEMBL1013846 | 0.91 | POLB (0.48) | MKNK1ESR2POLBMAPTADORA1 | |
| SCHEMBL1330087 | 0.90 | ESR2 (0.47) | MKNK1ESR2POLBPARP1TNKS2 | |
| SCHEMBL14872982 | 0.88 | MKNK1 (0.46) | MKNK1ESR2POLBMAPTNR1H2 | |
| SCHEMBL29710246 | 0.88 | MKNK1 (0.46) | MKNK1ESR2POLBMAPTNR1H2 | |
| SCHEMBL9951760 | 0.86 | ESR2 (0.48) | MKNK1ESR2PARP1TNKS2PARP2 | |
| SCHEMBL2511081 | 0.85 | POLB (0.43) | MKNK1ESR2POLBMAPTADORA1 | |
| SCHEMBL29899537 | 0.85 | MKNK1 (0.46) | MKNK1ESR2PARP1TNKS2PARP2 | |
| SCHEMBL30603343 | 0.85 | ESR2 (0.47) | MKNK1ESR2PARP1TNKS2PARP2 | |
| SCHEMBL19959250 | 0.85 | ADORA1 (0.49) | MKNK1ESR2PARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568954-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-06-18 | — | — | EP | disclosed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-08 | — | — | US | disclosed |
| CN-119677729-A | Cyclin Dependent Kinase (CDK) 12 and/or CDK13 inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4414365-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118480029-A | 2-Aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4400500-A1 | HALOGEN-SUBSTITUTED PYRIDAZINONE COMPOUND AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-12006325-B2 | Substituted furanopyrimidine compounds as PDE1 inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-06-11 | — | — | US | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-2475661-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011029842-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029842-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006325-B2 | Substituted furanopyrimidine compounds as PDE1 inhibitors | PDE4A, PDE5A, PDE3A | MKNK1 1835/4885ESR2 2202/4885POLB 1067/4885 |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | BCLAF1, BCL2L11, BCL2 | MKNK1 1031/4885ESR2 1680/4885POLB 3979/4885 |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | MKNK1 1835/4885ESR2 2202/4885POLB 1067/4885 |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | CDK2, PHKG1, PHKG2 | MKNK1 179/4885ESR2 2855/4885POLB 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.